---
title: "NBTX.US (NBTX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NBTX.US/news.md"
symbol: "NBTX.US"
name: "NBTX.US"
parent: "https://longbridge.com/en/quote/NBTX.US.md"
datetime: "2026-05-20T00:07:26.795Z"
locales:
  - [en](https://longbridge.com/en/quote/NBTX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NBTX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NBTX.US/news.md)
---

# NBTX.US (NBTX.US) — Related News

### [Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer](https://longbridge.com/en/news/286776980.md)
*2026-05-18T13:06:57.000Z*
> Nanobiotix reported promising Phase 2 data for its nanoradioenhancer NBTXR3 in treating stage 3 inoperable lung cancer. 

### [Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News](https://longbridge.com/en/news/286675157.md)
*2026-05-17T06:15:25.000Z*
> Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) i

### [Nanobiotix (NASDAQ:NBTX) Hits New 1-Year High  - Here's What Happened](https://longbridge.com/en/news/285538784.md)
*2026-05-07T11:18:43.000Z*
> Nanobiotix (NASDAQ:NBTX) shares reached a new 52-week high of $42.50 during trading, closing at $41.86. Analysts have mi

### [Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study  | NBTX Stock News](https://longbridge.com/en/news/285126081.md)
*2026-05-04T13:30:36.000Z*
> Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study | NBTX Stock News

### [Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Sees Significant Decline in Short Interest](https://longbridge.com/en/news/284122142.md)
*2026-04-26T20:42:43.000Z*
> Nanobiotix S.A. (NASDAQ:NBTX) experienced a significant decline in short interest, dropping 55.9% to 11,234 shares as of

### [Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating](https://longbridge.com/en/news/283702589.md)
*2026-04-22T16:45:19.000Z*
> Analyst Swayampakula Ramakanth from H.C. Wainwright has maintained a Buy rating on Nanobiotix with a price target of €34